Ventyx Reports Positive Phase IIa Results for Parkinson’s Drug VTX3232

Ventyx Biosciences has announced promising results from a Phase IIa trial of its CNS-penetrant NLRP3 inhibitor, VTX3232, in early-stage Parkinson’s patients. The 28-day open-label study in 10 individuals met its primary goal, demonstrating safety and tolerability with no drug-related adverse events.

VTX3232 showed strong pharmacokinetic performance, achieving target NLRP3 inhibition levels in both plasma and CSF. Biomarker analysis confirmed reduced levels of IL-1β, IL-18, IL-6, and hsCRP, indicating effective target engagement. Improvements were also noted in motor and non-motor symptoms based on MDS-UPDRS scores.

While PET imaging showed no acute changes—likely due to the short study duration—the data support advancing VTX3232 into a larger, placebo-controlled Phase II trial. Ventyx also plans to explore its use in other neurodegenerative disorders, including Alzheimer’s disease.

23-06-2025